We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Acer Therapeutics Inc (ACER) USD 0.01

Sell:$2.39 Buy:$2.42 Change: $0.02 (0.83%)
Market closed |  Prices as at close on 20 October 2021 | Switch to live prices |
Change: $0.02 (0.83%)
Market closed |  Prices as at close on 20 October 2021 | Switch to live prices |
Change: $0.02 (0.83%)
Market closed |  Prices as at close on 20 October 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Acer Therapeutics Inc. is a pharmaceutical company. The Company is focused on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. The Company's pipeline includes four programs: ACER-001, EDSIVO, ACER-801 and ACER-2820. The ACER-001 (Sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD). The EDSIVO (celiprolol) is a selective adrenergic modulator (SAM) for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation. The ACER-801 (osanetant) is a non-peptide tachykinin NK3 receptor antagonist for the treatment of induced Vasomotor Symptoms (iVMS). The ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19.

Contact details

One Gateway Center (300 Washington St.)
Suite 351
United States
+ ()

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$34.20 million
Shares in issue:
14.31 million
United States
US dollar

Key personnel

  • Christopher Schelling
    President, Chief Executive Officer, Director
  • Harry Palmin
    Chief Financial Officer, Chief Operating Officer
  • Jefferson Davis
    Chief Business Officer
  • John Klopp
    Chief Technical Officer
  • Matthew Seibt
    Chief Commercial Officer
  • Donald Joseph
    Chief Legal Officer, Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.